Enzolytics Inc.' focus is on the production and distribution of the Company's therapeutics and advancing its research and development programs. The Company sees the coming year as a transformative period in which it plans to advance its three synergistic therapeutic platforms generating multiple clinical products for human and veterinary use. The Company's IPF Immune therapeutic, a dietary supplement that supports the body's self-defense system, is now available in the U.S. and will be widely available through national retailers and their internet platforms and websites.

To meet demand, additional production of IPF Immune is ongoing. The Company is also advancing production of its ITV-1 anti-HIV therapeutic moving forward toward its use in Africa and EMA approval for use in Europe. In addition, the Company is advancing its AI platform technology and production of monoclonal antibodies against multiple infectious diseases for both humans and animals.

The Company plans to move forward with its technology for diagnostics, therapeutics, and vaccines, with each new discovery to be covered by PCT International Patent protection. Enzolytics IPF Immune is a nutritional dietary supplement that provides support to the body's natural immune system. The product supports normal immune function beneficial to maintaining good health.

The product is natural and tested for safety. This product enters the market as annual sales of American Dietary Supplements in North American reach $50.11 Billion. Dietary Supplement sales are forecast to increase to $77.10 Billion in 2028.

The Company's ITV-1 therapeutic is a therapy for treating individuals with HIV. It has been produced and earlier clinically tested in human trials under the Bulgarian Drug Agency requirements. The following positive therapeutic effects of ITV-1 have been demonstrated in prior European clinical trials.

Inhibits the infection of CD4 T-cells by HIV. Produced an 80.5% drop in viral loads. Replaces or complements current antiretroviral therapies.

Is less costly and less toxic. May be effective as a periodic therapy instead of a daily one. Is unaffected by HIV mutations that can hamper antiretroviral therapies (HAART).

Raises CD4 T-cell counts to healthier levels, a 68% increase in CD4+T-lymphocytes. Use achieved an increase in the CD4/CD8 index. Demonstrated an excellent effect on opportunistic infections.

Had good compatibility with other antiretroviral drugs. There was good tolerance without any side effects. Use resulted in a decrease in the absolute number and the relative percent of CD8 lymphocytes.

Boosts the immune system to fight HIV infections. The methodology implemented by the Company to produce monoclonal antibodies is proprietary and the subject of pending Patent Cooperation Treaty (PCT) International Patent applications. In the initial process step, Artificial Intelligence (computer analysis - A.I.) is used to identify conserved, immutable epitopes on the target virus utilizing Enzolytics' proprietary A.I. platform.

In the A.I. initial analysis step, the sequences (structure) of over 2 million Coronavirus isolates have been analyzed. From that analysis, 19 epitopes (target sites) have been identified as being immutable and conserved across all 2 million isolates curated. The Company production process is then employed to produce monoclonal antibodies targeting these identified conserved sites.

For HIV, the Company used A.I. to analyze 87,000 HIV isolates to identify 8 conserved epitopes sites against which monoclonal antibodies are being produced. As a part of the production process, 3 Dimensional models of these conserved targets are generated, and the targets are analyzed for linearity, accessibility by antibodies, and neutralizability by antibodies. Enzolytics' methodology for producing monoclonal antibodies is unique and innovative, unlike other biotech companies.

The Company's antibodies are produced from human "immune-B cells" obtained from convalescent individuals who have recovered from the target virus. The Company's monoclonal antibodies are not "humanized" but are fully human monoclonal antibodies where the original antibody affinity and specificity are maintained. The methodology starts with human "immune cells" obtained from convalescent individuals who have recovered from the virus.

From these human B cells, the Company then produces antibodies that target conserved immutable sites (neutralizable epitopes) on the virus' surface envelope proteins that will be ever-present, rendering the virus neutralizable even through mutation, thus voiding "virus escape". These antibodies also retain the original natural antibody's affinity and specificity and have a very low risk of immunogenicity when used as a therapeutic. Enzolytics is developing Class switched IgA1/2 Clone 3 Antibodies.

This therapy will expectedly provide a protective immunological defense against an initial exposure to HIV at mucosal surfaces, such as in the passage of the virus from mother to child through maternal breastfeeding. HIV mucosal infection plays a critical role in virus transmission and AIDS pathogenesis, affecting mucosal surfaces of the gastrointestinal tract early on by depleting CD4+ T helper cells independently of the virus transmission route. Although current antiretroviral therapy is intended to control HIV infection in most patients, it cannot eradicate the virus from the human host.

Therefore, the development and use of HIV microbicides (i.e., topical pre-exposure prophylaxis) have become a most promising approach to preventing HIV transmission. Thus, the development of Class switched Clone 3 IgA1/IgA2 is highly significant. In addition to the anti-HIV monoclonal antibody already produced and tested, Enzolytics is producing monoclonal antibodies targeting the additional seven conserved targets identified by the A.I. platform.

Producing antibodies for the treatment of Feline Leukemia Virus and Feline Immunodeficiency Virus is significant because these viruses are the most common infectious diseases in cats. There are more than 150 million cats in the U.S. and over 25% of households in America own cats. These Feline viruses a significant percentage of the cat population in the United States and around the world.

Production of monoclonal antibodies targeting these viruses will be more direct and the time to market will be significantly less than is the case required for monoclonal antibodies developed for the treatment of individuals. The Company has initiated discussions with animal health providers who express an interest in this technology and its end product. Enzolytics has a wholly owned Artificial Intelligence platform that drives: Early Drug Discovery and Development; Builds a valuable Intellectual Property Portfolio; Allows for strategic entry into the personalized medicine market.